Boehringer Ingelheim and Simcere are agreeing to develop SIM0709, a pre-clinical bispecific antibody, for treatment of inflammatory bowel disease (IBD). Boehringer Ingelheim receives global rights to the asset outside of greater China.

Originally developed by Simcere, SIM0709 simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23). As such, the TL1A/IL23p19 antibody blocks two core pathways that drive onset and progression of IBD.

In in-vitro primary cell studies and in-vivo animal studies, SIM0709 demonstrated long-acting, superior synergistic efficacy. Its performance outdistanced the combination of the two corresponding monotherapies.

IBD’s Impact, Antibody Treatment Potential

To put IBD’s impact in context, more than three million people worldwide are estimated to be affected. IBD is a lifelong and progressive condition that can result in frequent hospitalizations and surgeries, significantly impacting quality of life.

Currently, the available medical options are unable to fully prevent or reverse IBD’s various complications. Carine Boustany, Boehringer Ingelheim US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases, reflected on this.

“In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies,” Boustany said. “We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life-changing option.”

Also weighing in was Gaobo Zhou, Chief Investment Officer for Simcere Pharmaceutical Group.

“Simcere’s bispecific antibody SIM0709 was engineered with our proprietary multi-specific antibody platform with first-in-class potential for IBD treatment,” Zhou said. “Partnering with Boehringer Ingelheim, with its long‑term commitment and deep expertise in immunology, positions the compound for rigorous global development. Together we aim to accelerate the clinical development and advance a treatment option that could improve outcomes for patients worldwide.”

Financial Terms for Boehringer and Simcere

Simcere is eligible to receive an upfront payment for the agreement, as well as various milestones up to €1.058 million (US$1.266 million).

As of January 2026, Simcere has completed five out-licensing deals with a total potential value of US$4.6 billion.